Risk factors for Kaposi's sarcoma in patients with advanced human immunodeficiency virus disease treated with zidovudine. Zidovudine Epidemiology Study Group
- PMID: 8122950
Risk factors for Kaposi's sarcoma in patients with advanced human immunodeficiency virus disease treated with zidovudine. Zidovudine Epidemiology Study Group
Abstract
Background: Although the cause of Kaposi's sarcoma (KS) is unknown, its unique epidemiology suggests that an infectious, sexually transmitted agent or agents may contribute to its pathogenesis.
Methods: To assess the natural history of KS associated with the acquired immunodeficiency syndrome and to identify factors associated with its development, data were analyzed from a multicenter, observational cohort study of 1044 persons with the acquired immunodeficiency syndrome or the acquired immunodeficiency syndrome-related complex and a total CD4 cell count of less than 0.25 x 10(9)/L who were treated with zidovudine between April 1987 and April 1988. Records were reviewed bi-monthly. Follow-up continued for 2 years or until death.
Results: One hundred thirty-one patients (13%) had KS a study enrollment, and 143 developed KS (14%) during follow-up, with a 2-year actuarial risk of 21%. The probability of KS at 2 years for patients with initial CD4 cell counts of less than 0.1 x 10(9)/L was 25%, compared with 15% for those with counts of 0.1 x 10(9)/L or more. By logistic regression, a baseline CD4 cell count of less than 0.1 x 10(9)/L (relative odds, 1.43; 95% confidence interval, 1.04 to 1.95), homosexuality (relative odds, 3.71; 95% confidence interval, 1.82 to 7.56), cytomegalovirus disease (relative odds, 1.56; 95% confidence interval, 1.01 to 2.41), and white race (relative odds, 1.64; 95% confidence interval, 1.11 to 2.43) were independently associated with KS. Median survival after KS was 408 days, and KS was an independent predictor of death (relative hazard, 1.78; 95% confidence interval, 1.26 to 2.52).
Conclusions: Kaposi's sarcoma contributes to human immunodeficiency virus-related morbidity and mortality, especially among male homosexuals. This large cohort study provides further evidence for an association between risk for cytomegalovirus infection and KS.
Similar articles
-
Pneumocystis prophylaxis and survival in patients with advanced human immunodeficiency virus infection treated with zidovudine. The Zidovudine Epidemiology Group.Arch Intern Med. 1992 Oct;152(10):2009-13. Arch Intern Med. 1992. PMID: 1417373
-
Natural history of advanced HIV disease in patients treated with zidovudine. The Zidovudine Epidemiology Study Group.AIDS. 1992 Jul;6(7):671-7. AIDS. 1992. PMID: 1503686 Clinical Trial.
-
Epidemiology of AIDS-related Kaposi's sarcoma in Europe over 10 years. AIDS in Europe Study Group.AIDS. 1996 Jul;10(8):911-7. AIDS. 1996. PMID: 8828749
-
Epidemiology of Kaposi's sarcoma.Cancer Surv. 1991;10:5-22. Cancer Surv. 1991. PMID: 1821323 Review.
-
Kaposi's sarcoma: a reevaluation.Recent Results Cancer Res. 1995;139:275-96. Recent Results Cancer Res. 1995. PMID: 7541146 Review.
Cited by
-
Molecular genetics of Kaposi's sarcoma-associated herpesvirus (human herpesvirus-8) epidemiology and pathogenesis.Microbiol Mol Biol Rev. 2003 Jun;67(2):175-212, table of contents. doi: 10.1128/MMBR.67.2.175-212.2003. Microbiol Mol Biol Rev. 2003. PMID: 12794189 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous